Filing Details
- Accession Number:
- 0001062993-23-003479
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-02-14 17:18:41
- Reporting Period:
- 2023-02-10
- Accepted Time:
- 2023-02-14 17:18:41
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1267565 | Collegium Pharmaceutical Inc | COLL | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1734919 | R. Shirley Kuhlmann | C/O Collegium Pharmaceutical, Inc. 100 Technology Center Drive Stoughton MA 02072 | Evp And General Counsel | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-02-10 | 48,125 | $0.00 | 157,620 | No | 4 | A | Direct | |
| Common Stock | Acquisiton | 2023-02-10 | 25,739 | $0.00 | 183,359 | No | 4 | A | Direct | |
| Common Stock | Disposition | 2023-02-10 | 16,291 | $26.75 | 167,068 | No | 4 | F | Direct | |
| Common Stock | Disposition | 2023-02-10 | 7,755 | $26.75 | 159,313 | No | 4 | F | Direct | |
| Common Stock | Disposition | 2023-02-13 | 21,811 | $26.88 | 137,502 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | A | Direct | |
| No | 4 | F | Direct | |
| No | 4 | F | Direct | |
| No | 4 | S | Direct |
Footnotes
- Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2024, and the balance of the restricted stock units vest in equal annual installments over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock.
- Effective February 10, 2023, the Compensation Committee of the Board of Directors of the issuer determined that performance-vesting criteria were met with regard to an aggregate of 25,739 performance share units granted in the issuer's three prior fiscal years.
- Shares withheld by the issuer to satisfy applicable withholding taxes upon vesting of restricted stock units.
- Shares withheld by the issuer to satisfy applicable withholding taxes upon vesting of performance stock units.
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 28, 2022.
- The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.485 to $27.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (6).
Billionaire Hedge Funds
